You are herePharma News

Pharma News

Pharma sector to soon showcase new drugs: Vardhan

The Indian pharmaceutical sector would soon be showcasing new drugs for malaria, osteoporosis and diabetes, Union Minister for Science and Technology Harsh Vardhan said. These drugs are currently undergoing clinical trials, he said.

Sun Pharma, Israel university ink pact to develop anti-cancer drugs

Sun Pharmaceutical Industries has inked a pact with Israel's Technion university to develop anti-cancer drugs. The subsidiaries of the Mumbai-based drug firm and Technion - Israel Institute of Technology have entered into an exclusive worldwide research and license agreement, Sun Pharma said in a statement.

Gum disease treatment is linked with preventing Heart Disease

A new study from the Forsyth Institute is helping to shed more light on the important connection between the mouth and heart. According to research recently published online by the American Heart Association, scientists at Forsyth and Boston University have demonstrated that using an oral topical remedy to reduce inflammation associated with periodontitis, more commonly known as gum disease, also results in the prevention of vascular inflammation and can lower the risk of heart attack.

Genetically modified Salmonella may treat Cancer

Genetically modified Salmonella can kill cancer cells, suggests new research published in mBio, an American Society for Microbiology. one particular strain of salmonella found to be most effective at killing cancer cells and shrinking tumors, and also not toxic.

US FDA approved Aurobindo anesthesia supplement drug product

Aurobindo Pharma has received the final approval from the US Food and Drug Administration to manufacture and market Atracurium Besylate injection in single and multi-dose vials in the US market.

US FDA approved indication for Ethicon’s EVARREST Fibrin Sealant Patch

Ethicon, a part of J&J, received expanded FDA indication for its EVARREST Fibrin Sealant Patch to be used to help control bleeding during adult liver surgeries. The device is bioabsorbable and contains human thrombin and fibinogen proteins that participate in clot formation. It retains its strength and stickiness while it’s still around. EVARREST is a novel convergence of biologics and medical device that rapidly and reliably stops problematic bleeding during surgery on the first attempt in indicated patients. EVARREST is a fibrin sealant patch indicated for use with manual compression as an adjunct to hemostasis . The unmatched mechanism of action behind EVARREST drives rapid and durable clot formation. The technology is comprised of a flexible composite patch, which contains embedded human biologics (human thrombin and fibrinogen), which are proteins involved in the natural clotting process.

Ferring Pharma's new room temperature stable formulation of Pabal approved through EU

Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group active in global markets, announced that EU has approved its new room-temperature-stable formulation of Pabal (carbetocin) for intravenous (IV) administration.

Gilead submit US FDA approval for Fixed-Dose Combination of emtricitabine/tenofovir alafenamide for HIV treatment

Gilead Sciences has submitted a new drug application (NDA) to the FDA for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients aged 12 years and older, in combination with other HIV antiretroviral agents.

Novo Nordisk opens modern insulin formulation and filling facility in Russia

Novo Nordisk opens a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market.

Oncolytics REOLYSIN seeks US FDA orphan drug status to treat gastric cancer

Oncolytics Biotech Inc., a biotechnology company concentrated on the development of oncolytic viruses as potential cancer therapeutics. Company has presented an application to the US Food and Drug Administration (FDA) for REOLYSIN to get Orphan Drug Designation for the treatment of gastric cancer.